Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Vowst Prior Auth | OpenPayer
    Ask Trek AI about this page
    Currentblue cross blue shield - south dakotaPolicy 05.05.07

    Vowst (fecal microbiota spores, live-brpk) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.07 alerts

    Get alerted when Policy 05.05.07 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Vowst used to prevent recurrence of Clostridioides difficile infection in eligible adults, subject to approval criteria, exclusions, limitations, and benefit verification.

    Policy Summary
    Payerblue cross blue shield - south dakota
    PolicyVowst (fecal microbiota spores, live-brpk)
    Policy CodePolicy 05.05.07
    Change TypeNo material change
    Effective DateJul 17, 2023
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical records supporting recurrent CDI, qualifying stool testing, age at least 18 years, at least three CDI episodes within the past 12 months, and an adequate response to standard-of-care antibiotic therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3+Required CDI episodes
    30 daysInitial authorization
    12 capsLifetime quantity limit
    Not coveredActive CDI treatment

    Coverage Criteria

    Initial therapy: prevention of recurrent CDI

    Covered for a one-time 30-day authorization when all of the following are met.

    Initial approval

    • Age: Member is 18 years of age or older.>= 18 years
    • Recurrence history: Member has had three or more episodes of CDI within the past 12 months, including the most recent episode.>= 3 episodes within the past 12 months
    • Recent recurrent CDI episode

      • Stool frequency: At least 3 unformed stools per day for 2 consecutive days.>= 3 unformed stools per day for 2 consecutive days
      • Laboratory confirmation: Stool test confirms the presence of C. difficile toxin or toxigenic C. difficile.
      • Response to antibiotic therapy: Adequate clinical response, such as resolution of symptoms, following standard-of-care antibiotic therapy, such as vancomycin or fidaxomicin.

    Non-formulary exception

    A non-formulary product may be covered when the approval criteria and all of the following are met.

    • Supported indication: The requested drug is used for an FDA-approved indication or an indication supported in current literature compendia, such as AHFS, Micromedex, or current accepted guidelines.

      Diagnostic testing or laboratory results are required when applicable.

    • Dose and quantity: The prescribed dose and quantity fall within FDA-approved labeling or dosing guidelines found in current literature compendia.
    • Formulary alternatives: All covered formulary alternative drugs on any tier are ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would have adverse effects.

      Documentation must include prior treatment failure, severity of the adverse event when applicable, dosage and duration of prior treatment, or a contraindication to formulary alternatives.

    Vowst is not covered when requested to treat active Clostridioides difficile infection (CDI). Its covered use is prevention of recurrent CDI following antibacterial treatment, not treatment of an active CDI episode.

    Vowst is considered not medically necessary when the member does not meet the initial approval criteria for prevention of recurrent CDI, including the requirements for age, recurrent CDI history, qualifying stool frequency, positive stool testing, and adequate clinical response to standard-of-care antibiotic therapy.

    Initial Therapy Criteria

    Prevention of recurrent CDI

    Authorization of 30 days for a one-time treatment may be granted for prevention of recurrent CDI when all of the following criteria are met.

    • Age and recurrence history: Member is 18 years of age or older and has had three or more episodes of CDI within the past 12 months, including the most recent episode.>= 18 years; >= 3 episodes within the past 12 months
    • Recent recurrent CDI episode

      • Stool frequency: At least 3 unformed stools per day for 2 consecutive days.>= 3 unformed stools per day for 2 consecutive days

    Coverage Parameters

    Member age
    Minimum age18 years
    Eligibility requirementMember must be 18 years of age or older
    Covered populationAdults meeting the prevention-of-recurrent-CDI criteria
    Recurrent CDI episodes
    Required episode countThree or more CDI episodes
    TimeframeWithin the past 12 months
    Most recent episodeThe count must include the most recent episode

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required for Initial Approval

    Submit prior authorization documentation for Vowst as a one-time 30-day treatment for prevention of recurrent CDI. Approval requires documentation that the member is at least 18 years old, has had at least three CDI episodes within the past 12 months including the most recent episode, and meets the requirements for a recent recurrent episode.

    • Document at least 3 unformed stools per day for 2 consecutive days during the recent episode.
    • Provide stool testing confirming C. difficile toxin or toxigenic C. difficile.
    • Document an adequate clinical response, such as resolution of symptoms, after standard-of-care antibiotic therapy.
    Documentation Required

    Non-Formulary Exception Documentation

    For a non-formulary request, document that Vowst is being prescribed for an FDA-approved indication or an indication supported by current compendia or accepted clinical guidelines, and that applicable diagnostic testing or laboratory results are available.

    Clinical Background

    Vowst (fecal microbiota spores, live-brpk) is indicated to prevent recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent CDI. It is not indicated for treatment of active CDI.

    Definitions and Indication

    FDA-approved indication
    IndicationPrevention of recurrence of Clostridioides difficile infection (CDI)
    Eligible populationIndividuals 18 years of age and older
    Treatment contextFollowing antibacterial treatment for recurrent CDI
    Treatment of CDI
    Active CDI treatmentVowst is not indicated for the treatment of CDI
    Covered usePrevention of CDI recurrence rather than treatment of an active episode
    Coverage distinction

    Required Prior Therapy

    StepRequirementClinical response
    1Prior standard-of-care antibiotic therapy, such as vancomycin or fidaxomicinAdequate clinical response, such as resolution of symptoms, following therapy

    Quantity Limits

    Vowst capsules
    ProductVowst capsules
    Quantity per course1 bottle
    Capsules and frequency limit12 capsules per lifetime
    Policy Summary
    Payerblue cross blue shield - south dakota
    PolicyVowst (fecal microbiota spores, live-brpk)
    Policy CodePolicy 05.05.07
    Change TypeNo material change
    Effective DateJul 17, 2023
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical records supporting recurrent CDI, qualifying stool testing, age at least 18 years, at least three CDI episodes within the past 12 months, and an adequate response to standard-of-care antibiotic therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaCoverage ParametersProvider Actions and AuthorizationClinical BackgroundDefinitions and IndicationRequired Prior TherapyQuantity Limits
    Laboratory confirmation:
    Stool test confirms the presence of C. difficile toxin or toxigenic C. difficile.
  1. Response to antibiotic therapy: Adequate clinical response, such as resolution of symptoms, following standard-of-care antibiotic therapy, such as vancomycin or fidaxomicin.
  2. Unformed stools
    Stool frequencyAt least 3 unformed stools per day
    DurationFor 2 consecutive days
    Qualifying episodeThe recent recurrent CDI episode must meet both the frequency and duration requirements
    Lifetime quantity limit
    Quantity limit1 bottle
    Capsule count12 capsules per bottle
    Lifetime limitOne bottle containing 12 capsules per lifetime
    • Provide the prescribed dose and quantity and show that they fall within FDA-approved labeling or accepted compendia dosing guidelines.
    • Meeting the underlying Vowst approval criteria may satisfy some or all portions of the non-formulary exception criteria.
    Step Therapy

    Prior Antibiotic Therapy and Formulary Alternatives

    Document the member’s prior standard-of-care antibiotic therapy and address all covered formulary alternatives on any tier before requesting non-formulary Vowst.

    • Document an adequate clinical response after standard-of-care therapy, such as vancomycin or fidaxomicin.
    • For each applicable formulary alternative, provide chart notes or other documentation showing that it was ineffective, previously ineffective, less effective, caused an adverse effect, or is contraindicated.
    • Include prior-treatment dosage and duration, treatment-failure details, and the severity of any adverse event.
    Documentation Required

    Required Clinical Documentation

    Include medical records, chart notes, and/or laboratory results supporting the diagnosis and recurrence of CDI. The submission must include laboratory confirmation of C. difficile toxin or toxigenic C. difficile.

    • Document recurrent CDI.
    • Provide stool test results confirming the presence of C. difficile toxin or toxigenic C. difficile.
    Documentation Required

    Non-Formulary Alternative Documentation

    When the requested product is non-formulary, submit evidence that covered formulary alternatives are ineffective, have been ineffective, would not be as effective as Vowst, caused adverse effects, or are contraindicated.

    • Include chart notes or other supporting documentation.
    • Specify prior treatment dosage and duration, treatment failure, the severity of any adverse event, or the applicable contraindication.
    Denial Risk

    Noncovered Use or Unmet Criteria

    Coverage is not available when Vowst is requested to treat active CDI rather than prevent recurrence. Vowst is also not medically necessary when the member does not meet the stated approval criteria.

    • Use Vowst for prevention of recurrent CDI, not treatment of CDI.
    • Approval criteria include age 18 or older, at least 3 CDI episodes within the past 12 months including the most recent episode, and the required clinical findings and testing for a recent recurrent episode.
    • Requests that fail to document the qualifying criteria, required laboratory confirmation, adequate response to standard-of-care antibiotics, or applicable non-formulary requirements may be denied.
    Requests to treat active CDI do not meet the indicated use